Background: Macular edema is the most common cause of vision loss among patients with diabetes.
D
iabetes affects approximately 26 million patients in the United States, accounts for $1 in $10 spent on health care, and is the leading cause of new-onset blindness among adults (1) . Dilated eye examinations identify diabetic retinopathy, which ranges from mild (retinal hemorrhages) to severe (ischemia-induced neovascularization and fibrovascular proliferation, with potential hemorrhage, retinal detachment, or glaucoma). These examinations also identify diabetic macular edema (DME), which is central retinal edema resulting from increased vascular permeability of the retina.
Diabetic macular edema affects central vision and is the most common cause of vision loss in patients with diabetes (2) . Its prevalence is 9% among these patients (3) , with approximately 75 000 new cases annually (4) . Untreated DME can cause progressive vision decline (5) and medical costs that are 29% higher than those for unaffected patients with diabetes (6) .
The goal of DME treatment is to stop decline and, ideally, to recover vision. Successful treatment can enable a patient to resume driving, depending on the degree of vision impairment. Standard therapy has been macular laser treatment, which targets leaking microaneurysms and mildly stimulates subretinal cells to decrease edema. More recently, treatment of this condition has included intravitreal (intraocular) injections of triamcinolone acetonide or vascular endothelial growth factor (VEGF) inhibitors, which reduce vascular permeability and allow fluid reabsorption.
Unlike laser treatment, which has potentially longlasting effects, injections require periodic retreatment. Vascular endothelial growth factor inhibitors include bevacizumab, ranibizumab, and the newer VEGF Trap-Eye (aflibercept). In contrast to monotherapy, combination therapies of laser treatment and intravitreal injections aim to provide the long-term benefits of laser treatment and short-term benefits of fluid reabsorption. Treatment costs per injection differ substantially, from approximately $50 (off-label bevacizumab) to $1200 (U.S. Food and Drug Administration-approved ranibizumab) (7) (8) (9) (10) (11) .
Each strategy is well-studied, but no trial compares all therapies and few compare costs. Evidence on costeffectiveness is conflicting. The U.K.'s National Institute for Health and Clinical Excellence evaluated an industryconducted modeling analysis of ranibizumab, and it found the cost-effectiveness of VEGF inhibitors to be unconvincing relative to that of laser treatment (12) . Two published studies reached the opposite conclusion; however, they did not consider lifetime costs and benefits nor compare all major treatments (13, 14) .
Our study compares 6 strategies for lifetime management of DME. By comparing therapy with no treatment, we evaluate the societal effect of undiagnosed DME, which is particularly important given the increasing prevalence of diabetes. Diagnosis and proper management of DME depends on appropriate referral from primary care clinicians, who also play an important role in shared decision making with patients. Building on a relationship of long-standing trust with their primary care providers, patients often seek advice and second opinions about treatments offered by specialists. Understanding the options, vision benefits, and tradeoffs in therapy for DME will support and inform such conversations as part of comprehensive diabetes care.
METHODS

Overview
We developed a decision-analytic Markov cohort model of the natural history and treatment of DME, integrating mortality, visual acuity, treatment costs, complications, and societal costs. The model compared the effect on health, longevity, and costs of the following management strategies: no treatment; monotherapy with a VEGF inhibitor (ranibizumab, 0.3 mg); monotherapy with triamcinolone, 4 mg; laser monotherapy; combination therapy with laser treatment plus a VEGF inhibitor; and combination therapy with laser treatment plus triamcinolone. We translated vision and complications into utility-based quality-oflife measures and analyzed these from a societal perspective, broadly considering all lifetime costs and benefits, regardless of who benefited (15) (16) (17) (18) (19) (20) .
Patient Cohort
The main cohort included patients with type 1 or 2 diabetes and clinically significant DME. In the model, 50% were men, age was 63 years, and visual acuity of the better eye was 20/63. Patients had no previous cataract surgery and did not receive treatment of DME within 4 months. These characteristics were similar to those of the baseline populations of major clinical trials of DME (21-33).
Disease Progression
Health states of DME reflected vision (visual acuity categories 1 through 6 [ Table 1 ]), treatment status, and complications (Figure 1) . Because longitudinal data on the natural history of progression of DME are limited, we used expert opinion and calibration to the DRCR.net (Diabetic Retinopathy Clinical Research Network) study cohort to estimate long-term changes without treatment (transition probabilities were calculated using a Markov model with constant progression rates [Supplement, available at www .annals.org]) (34) . Table 2 shows input values (see Table 4 of the Supplement for visual acuity outcomes with and without treatment and 
Context
Current therapies for diabetic macular edema include laser treatment, intraocular injections of triamcinolone or drugs that inhibit vascular endothelial growth factor (VEGF), and combinations of laser treatment plus injections of triamcinolone or a VEGF inhibitor.
Contribution
The investigators compared the lifetime costs and effectiveness of alternative treatments by using mathematical models that incorporated what was already known about each treatment.
Caution
Long-term outcome data are limited.
Implication
The most effective treatment of diabetic macular edema is VEGF inhibitor injection with or without laser treatment. This therapy is as cost-effective as acceptable treatments for many other conditions. We used smaller studies in sensitivity analyses to explore these differences (44 -57) . We modeled key complications individually: arterial thromboembolic events, glaucoma (controlled and severe or uncontrolled), and cataracts. We divided complications into major (for example, endophthalmitis) and minor (for example, eye irritation) categories (Supplement). We captured 1-time costs and quality-of-life decrements for acute complications and monthly costs and quality-of-life decrements for chronic complications ( Table 2 ).
-The Editors
In the main analysis, we assumed treatment of the better eye for a direct and predictable effect on visionrelated quality of life. Treatment was received for 1 year except when stopped earlier because of complications (arterial thromboembolic events or uncontrolled glaucoma). We calibrated the model to match the average and the distribution of number of treatments for each strategy in clinical trials (Supplement).
We selected a 1-year treatment period for consistency with primary trial end points and because greater crossover among treatment groups occurred in extended 2-and 3-year follow-up. For progression of DME after treatment, we modeled visual decline at a slower rate in strategies involving laser treatment (because clinical benefit from this therapy can be long-standing, in contrast to the short-term effect of injections) (58) . We evaluated each assumption in sensitivity analyses.
Additional simplifying assumptions included no crossover among treatments and no treatment resumption once a treatment had been discontinued (because of an arterial thromboembolic event or uncontrolled glaucoma or-in the main analysis-after 1 year of therapy). We made these assumptions to keep the modeling tractable and because of limited data (Supplement). We validated clinical outcomes by comparing the outcomes of the no-treatment group with the expected cumulative risk for blindness with untreated DME (Table 2 of the Supplement).
Mortality
We obtained age-and sex-specific death rates, adjusted for diabetes or diabetic retinopathy, from U.S. life tables (Table 2) (59). We assumed DME and its treatments did not directly affect mortality and validated life-expectancy projections against clinical trials. We evaluated alternative mortality scenarios in sensitivity analyses (Supplement).
Quality of Life
Our primary health outcome was quality-adjusted lifeyears (QALYs) gained, allowing comparison with other treatments that extend life and improve health in various domains (60) . Previous studies have correlated quality-oflife weights with visual acuities, using time-tradeoff and standard gamble methods (61) (62) (63) (64) . We selected the most commonly cited utility values in the ophthalmology costeffectiveness literature (65, 66) for our main analysis, computed from the following equation (67) This was the best-fit equation from multiple linear regression modeling of time-tradeoff utilities for patients across a spectrum of eye diseases, including diabetic retinopathy, age-related macular degeneration, and retinal dystrophies (67) . Our inputs ( Table 1) . Solid arrows represent possible worsening (progression) within a given month, and dashed arrows represent the potential for improvement or progression within a given month while receiving treatment. On-treatment states are subject to risk for complications (arterial thromboembolic events, glaucoma, cataracts, and other major or minor complications). In the base case, treatment was stopped after 1 y for all strategies or sooner if an arterial thromboembolic event or severe glaucoma occurred. VEGF ϭ vascular endothelial growth factor. * Off or after treatment. 
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Costs
We obtained costs from published Medicare reimbursement and expenditures (7, 8) and average wholesale prices (9 -11) . We adjusted costs to 2010 U.S. dollars by using Consumer Price Index deflators (68) . Our main analysis included direct and indirect (time) costs ( Table 2) . We obtained time costs, which comprised costs from blindness and caregiver costs, from the literature. Costs from blindness represented non-eye-related medical costs in excess of those in patients with normal vision (for example, from falls or depression) (65, 68, 69) . Caregiver costs represented caregiver time: lost potential wages based on U.S. Bureau of Labor Statistics data, up to $19 991 annually (visual acuity category 6 in our main analysis) (70, 71).
Statistical Analysis
All analyses used TreeAge Pro 2009 (Williamstown, Massachusetts). Additional technical details are available in the Supplement. 
org).
‡ In cases where values on a normal distribution would fall below 0, the distribution was truncated to a minimum value of 0. § Costs of blindness were obtained from reference 69. Estimates were derived from the costs of any Medicare service not related to eye care or performed by an ophthalmologist/optometrist on the basis of Medicare claims data. Costs were adjusted for potential confounders via multivariate regression modeling and calculated as the amount in excess of non-eye-related costs with normal vision. Highlighted costs of blindness included injury, depression, and skilled nursing/long-term care facility utilization. Caregiver costs were obtained from reference 70. Estimated hours per week of caregiver assistance were based on results of the Age-Related Macular Degeneration Health and Impact Questionnaire administered to a sample of age-related patients with macular degeneration. The cost of caregiver time was calculated as forfeited wages, from Consumer Price Index-adjusted U.S. Bureau of Labor Statistics hourly nonfarm, nonsupervisory seasonally adjusted wages (71) . ¶ Utility decrements represent the amount by which the quality-of-life utility in a given state is reduced because of a complication. In the case of an acute decrement, the amount shown is subtracted from quality of life only in the cycle (month) in which the complication occurred; a recurrent decrement is applied every month (for complications with chronic effects, such as glaucoma or stroke).
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Cost-Effectiveness Analysis
Our primary outcome was the incremental costeffectiveness ratio (ICER) of cost per QALY gained. Secondary outcomes included treatments, vision changes, complications, and life expectancy. We discounted costs and benefits 3% annually over a lifetime horizon (72).
Sensitivity Analysis
Sensitivity analyses assessed whether the main findings depended critically on specific assumptions or inputs. We conducted more than 250 deterministic sensitivity analyses. Probabilistic sensitivity analysis to quantify total uncertainty involved random sampling from independent distributions for each model input 1000 times, and repeating the main analysis with each set of samples. Generally, we assumed ␤ distributions for probabilities and utilities and normal distributions for costs ( Table 2) . Table 23 of the Supplement shows uncertainty ranges.
Role of the Funding Source
The Agency for Healthcare Research and Quality had no role in the analysis or reporting of the data or the design or conduct of the study. Table 3 shows the effect of each strategy on visual acuity outcomes, complications, costs, and QALYs. Combination therapy with laser treatment plus triamcinolone yielded the most time with visual acuity of 20/30 or better. However, VEGF inhibitor treatment, as monotherapy or combined with laser treatment, yielded the longest length of life with any improvement in visual acuity over baseline. Outcomes depended on the use of laser treatment, such that VEGF inhibitor strategies resulted in either a slightly higher or a lower lifetime risk for blindness than combination therapy with laser treatment plus triamcinolone after 1 year of treatment ( Table 3 and Table 2 of the Supplement). All strategies that included triamcinolone had the highest risk for nonminor complications because of a greater risk for glaucoma and cataract. Patients received approximately 8 VEGF inhibitor injections, 2 to 3 triamcinolone injections, or 2 to 3 laser treatments during the first year for each strategy.
RESULTS
Visual Acuity Outcomes and Complications
QALYs
Combination therapy with laser treatment plus a VEGF inhibitor achieved the largest overall gains in QALYs, closely followed by monotherapy with a VEGF inhibitor; this finding is consistent with clinical outcomes (Table 3 and Figure 2) . No treatment, laser monotherapy, and triamcinolone monotherapy achieved substantially fewer QALYs gained than the other management strategies. Because of complications, triamcinolone monotherapy was inferior to no treatment.
Cost-Effectiveness
All therapies were cost-saving compared with no treatment except for laser monotherapy, which had lifetime costs similar to no treatment in the main analysis (Figure 2 [top] and Table 3 ). Combination therapy with laser treatment plus a VEGF inhibitor cost $12 410 per QALY gained over combination therapy with laser treatment plus triamcinolone with 1 year of treatment (Figure 2, top) and $24 477 per QALY gained with lifetime treatment (Figure  2, bottom) . Injections with a VEGF inhibitor yielded more health benefits at lower cost than laser monotherapy, triamcinolone monotherapy, and no treatment and seemed more cost-effective in combination with laser treatment than as monotherapy because monotherapy was slightly less effective and slightly more expensive ( Table 3 and Figure 2 ).
Sensitivity Analysis
The most important clinical uncertainties surrounding treatment of DME include whether combination therapy with laser treatment plus a VEGF inhibitor is superior to monotherapy with a VEGF inhibitor and which types of patients may be better suited for monotherapy; the choice of VEGF inhibitor, given their vastly different costs and adverse effect profiles; and the benefits and costs that may accrue if treatment is continued over a patient's lifetime or extended to include the patient's other eye.
Choosing Between Monotherapy With a VEGF Inhibitor and Combination Therapy With Laser Treatment Plus a VEGF Inhibitor
Although the main analysis clearly indicates that combination therapy and VEGF inhibitors are cost-effective for DME, the advantage of combination therapy with laser treatment over monotherapy with VEGF inhibitors is less certain. The lifetime differences in costs and benefits of combination therapy versus monotherapy are only 0.03 QALYs (11 quality-adjusted life-days) and $1240. Monotherapy with a VEGF inhibitor becomes cost-effective in patients with DME who experience smaller quality-of-life decrements in progressing from moderate to severe vision loss, who are less likely to lose vision, or whose rate of visual decline is unlikely to be slowed by laser treatment (Tables 5 to 8 of the Supplement) (11, 12) . Furthermore, monotherapy with a VEGF inhibitor becomes costeffective if the cost of a laser treatment exceeds that of a VEGF inhibitor injection (Supplement).
However, combination therapy with laser treatment plus a VEGF inhibitor performs better than monotherapy with a VEGF inhibitor even if 0.5 mg of ranibizumab is used (an alternative dose in clinical practice, as opposed to 0.3 mg in our base case). Our main analysis may actually understate the benefits and cost-effectiveness of combination therapy with a VEGF inhibitor because the RESTORE trial provided our estimates of the effectiveness of monotherapy (21) and many RESTORE patients had received laser treatment before the trial, potentially aug-
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Cost-Effectiveness of Treatment of Diabetic Macular Edema www.annals.orgmenting the benefit from VEGF injections. This finding effectively made monotherapy outcomes closer to those of combination therapy in the DRCR.net trial, narrowing the apparent difference in effectiveness between monotherapy and combination therapy-a potential source of bias in favor of higher effectiveness from monotherapy with a VEGF inhibitor. Even so, we believe that the effect estimate from the RESTORE trial is appropriate for use in the main analysis because it better reflects clinical practice in which many patients have received laser treatment.
Choice of a VEGF Inhibitor
Bevacizumab. Bevacizumab is also effective for DME at approximately 4% of the cost of ranibizumab, although it is not currently approved by the U.S. Food and Drug Administration for treatment of DME and concerns have been raised about increased risks for endophthalmitis or vascular complications related to systemic absorption (Supplement). Given noninferiority to ranibizumab in CATT (Comparison of Age-Related Macular Degeneration Treatments Trial) (73, 74) and results of smaller trials with bevacizumab in patients with DME (44, 75, 76) , we repeated analyses using bevacizumab prices with and without doubled risk for endophthalmitis, recognizing that recent cases of endophthalmitis attributed to contaminated bevacizumab (77) . Even after doubling the risk for endophthalmitis with bevacizumab, laser treatment plus ranibizumab cost more than $3.5 million per QALY gained compared with laser treatment plus bevacizumab ( Table  15 of the Supplement).
Data from CATT and other trials have raised the question of whether bevacizumab has a higher mortality rate than ranibizumab (possibly from greater systemic absorption of bevacizumab). Laser treatment plus ranibizumab may be more cost-effective ( Table 15 of the Supplement) if bevacizumab yields a hazard ratio for death greater than 2.6 (vs. 2.2 with all other strategies). However, bevacizumab-associated mortality is unlikely to be this marked (73, 74) .
VEGF Trap-Eye. Although not approved by the U.S. Food and Drug Administration for DME, VEGF TrapEye is another VEGF-targeted agent used clinically. Its cost-effectiveness depends on dose, cost, and frequency of treatment (Tables 18 to 20 of the Supplement). Relative to laser treatment plus triamcinolone, VEGF Trap-Eye yielded an ICER of $23 519 when 2 mg was administered and $3616 when 0.5 mg was administered (over 1 year as in the DA VINCI (DME And VEGF Trap-Eye: Investigation of Clinical Impact) trial (45) . Just as no dose-related difference in outcomes was seen in the DA VINCI trial, alternative 1-year treatment outcomes did not change our conclusions. With lifetime treatment, lower-dose and lessfrequent VEGF Trap-Eye may be more cost-effective than ranibizumab if efficacy is the same. ICER ϭ incremental cost-effectiveness ratio; QALY ϭ quality-adjusted life-year; VEGF ϭ vascular endothelial growth factor. * Number of complications occurring during treatment, in excess of baseline. † Values were normalized to the no-treatment group to adjust for starting visual acuity distributions. ‡ Undiscounted, over lifetime follow-up. § Relative to the next best alternative. Treatment administered over 1 y, with subsequent lifetime follow-up. ¶ Unlike in other strategies, the lifetime QALYs associated with triamcinolone therapies decrease in going from the 1-y treatment model to the lifetime model. This is due to an increased likelihood of glaucoma and cataract with lifetime treatment (see Complications section in the Supplement, available at www.annals.org, for further details). ** Baseline comparator for calculation of ICER. Represents the reference point on the cost-effectiveness frontier (Figure 2) . † † Costs more and is less effective than another strategy. ‡ ‡ Baseline defined by the number of complication events in the untreated (clinical observation) group. § § Treatment administered over lifetime.
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Bilateral Disease
Diabetic macular edema often affects both eyes, although it may be asymmetric. However, data are not available to estimate utility gains from treating both eyes (such benefits as improved stereopsis or wider visual field). Although our main analysis assumed treatment of the eye with the better visual acuity, we used 2 approaches to consider treatment of both eyes.
Assuming symmetric disease, bilateral treatment, and doubled treatment costs, combination therapy with laser treatment plus a VEGF inhibitor cost $28 236 per QALY gained over combination therapy with laser treatment plus triamcinolone. Alternatively, if the need for therapy to the second eye is assumed to be more modest by using a method accepted by the National Institute for Health and Care Excellence (multiplying the 1-eye ICER by 1.5) (12), combination therapy with laser treatment plus a VEGF inhibitor costs $18 615 per additional QALY.
Lifetime Treatment
Because most patients will receive treatment for longer than 1 year, we also considered different treatment frequencies over a lifetime. Vision was assumed to remain stable while receiving treatment (extrapolating from the DRCR.net and READ-2 trials, in which patients maintained benefit at 24 and 36 months despite declining frequency of treatment) (23) (24) (25) (26) (27) (28) .
On the basis of data from the DRCR.net trial, we assumed 3 VEGF inhibitor injections and 1 triamcinolone injection per year, 1 laser treatment every other year when laser treatment was received as monotherapy, and no additional laser treatments with combination therapy (Supplement) (23) (24) (25) (26) . In this scenario, combination therapy with laser treatment plus a VEGF inhibitor was preferred, costing $26 477 per QALY gained over combination therapy with laser treatment plus triamcinolone ( Table 3 and Figure 2 [bottom]). However, if additional laser treatments are required to maintain vision in patients receiving combination therapy, monotherapy with a VEGF inhibitor may be superior, reflecting laser-associated complications and costs (Table 16 and Figure 1 of the Supplement). Strategies involving VEGF inhibitors were consistently preferred even when continuing treatment at the same frequency as in the first year ( Table 16 and Table 17 of the Supplement).
Additional Deterministic Sensitivity Analysis
The preferred strategy remained unchanged from the main analysis in scenarios examining alternative assumptions about treatment outcomes, complications, glycemic control, cataract, glaucoma, and mortality ( Table 2 and Tables 4 to 22 of the Supplement).
Probabilistic Sensitivity Analysis
Allowing for uncertainty of all model variables simultaneously, VEGF inhibitor injections, with or without laser treatment, were cost-effective in 97.1% of simulations using a willingness-to-pay threshold of $50 000 per QALY (59.5% probability of combination therapy with laser treatment plus a VEGF inhibitor, 37.6% probability of monotherapy with a VEGF inhibitor, and 2.9% probability of combination therapy with laser treatment plus triamcinolone being most cost-effective, respectively). With a $100 000 willingness-to-pay threshold, VEGF inhibitor strategies were cost-effective in 99.7% of simulations (58.4% probability of combination therapy with laser treatment plus a VEGF inhibitor, 42.3% probability of monotherapy with a VEGF inhibitor, and 0.3% probability of combination therapy with laser treatment plus triamcinolone being most cost-effective, respectively) ( Figure 2 of the Supplement). 
DISCUSSION
Diabetic macular edema is a major cause of diabetesrelated morbidity, and diagnosis and treatment depend on timely referral from primary care clinicians. Our analysis indicates that treatment is cost-saving (except for laser monotherapy, which has costs similar to no treatment in our main analysis) and that all treatments other than triamcinolone monotherapy increase quality of life and lifetime QALYs. With lifetime treatment, all treatment strategies were cost-saving compared with no treatment. A visual "review of systems" and regular referrals to an ophthalmologist are important, because patients may not volunteer symptoms of DME (mild visual decline, distortion, or diminished contrast sensitivity). Dilated ophthalmologic examinations are necessary to identify DME, and early treatment has the best prognosis for visual recovery.
Other recent cost-effectiveness analyses addressing DME lack consensus about preferred treatment (12) (13) (14) . In evaluating industry-modeled analysis of DME treatments, the National Institute for Health and Clinical Excellence did not recommend covering ranibizumab, citing model limitations and insufficient evidence of costeffectiveness (12) . Our analysis explicitly addressed these limitations-including treatment beyond 1 year, disease progression after treatment, and uncertainty about bilateral disease-by relying on assumptions, including regular treatment, maintenance of treatment-induced vision gain, and estimation techniques for bilateral disease. We ultimately found that combination therapy with laser treatment plus a VEGF inhibitor provides reasonable value.
The most cost-effective treatment in our analysis was combination therapy with laser treatment plus injections of a VEGF inhibitor, with other reasonable options being monotherapy with a VEGF inhibitor and combination therapy with laser treatment plus triamcinolone. However, laser monotherapy and triamcinolone monotherapy were not cost-effective (lifetime costs and quality of life were similar to those of no treatment). The superiority of combination therapy to laser monotherapy or triamcinolone monotherapy reflects better vision outcomes in clinical trials ( Table 4 of the Supplement).
Our analysis is limited by outcomes for strategies obtained from different publications; however, most relevant trials were part of the DRCR.net study. Furthermore, laser treatment and triamcinolone act via different mechanisms and it is clinically reasonable to expect that combining the 2 treatments yields a better result than monotherapy with each. For example, reduction of acute edema from triamcinolone may improve laser uptake and efficacy.
Combination therapy with laser treatment plus a VEGF inhibitor remained cost-effective in many sensitivity analyses that reflected clinical uncertainties. However, because of lack of available data, we had limited ability to model treatment outcomes for some clinical uncertainties, including treatment for both eyes, crossover from 1 treatment to another, and lifelong treatment. We aimed to make clinically realistic assumptions to evaluate these scenarios. For example, we used 2 methods to estimate the cost-effectiveness of treating both eyes and found that VEGF inhibitors remained cost-effective regardless of the method chosen. Combination therapy with laser treatment plus a VEGF inhibitor also remained cost-effective in most lifelong treatment scenarios assuming treatment with 0.3 mg of ranibizumab. However, if treatment is more fre- Discounted lifetime costs and QALYs associated with the 6 strategies. The top panel represents the main analysis, with 1 y of treatment with lifetime follow-up. The bottom panel represents lifetime treatment with 3 VEGF inhibitor injections per year (monotherapy or combination therapy), 1 triamcinolone injection per year (monotherapy or combination therapy), 1 laser treatment every other year in laser monotherapy, and no additional laser treatments in combination therapy strategies. The solid black line indicates the cost-effectiveness frontier, which represents the most cost-effective series of strategies (achieving the greatest relative benefit for the lowest cost). The ICERs are indicated in dollars per QALY, representing the cost of additional effectiveness relative to the next best strategy (this figure compares the preferred strategy of laser therapy plus VEGF inhibitors with laser therapy plus triamcinolone, with an ICER of $12 410/QALY with 1 y of treatment and an ICER of $26 477/QALY with treatment over a lifetime). The strategies that form the cost-effectiveness frontier (laser therapy plus triamcinolone and laser therapy plus VEGF inhibitors, each depicted with a solid black circle) dominate those to the right of the frontier (gray circles) because they are more cost-effective and cost less (strong dominance) or have a better cost-effectiveness ratio (weak dominance). ICER ϭ incremental costeffectiveness ratio; QALY ϭ quality-adjusted life-year; VEGF ϭ vascular endothelial growth factor.
Original Research Cost-Effectiveness of Treatment of Diabetic Macular Edema quent or less effective than in the main analysis, lifetime combination therapy with laser treatment may not be superior to monotherapy with a VEGF inhibitor. Monotherapy with a VEGF inhibitor achieved outcomes and had costs similar to those of combination therapy with laser treatment plus a VEGF inhibitor. The modest additional benefit of laser treatment may be understated in our model because effectiveness estimates for monotherapy with a VEGF inhibitor were based on trials in which many patients had previously received laser treatment and thus were less likely to show large benefits from combination therapy relative to VEGF inhibitor monotherapy. The benefits of combination therapy may vary among patients, according to their relative disutility from visual decline versus risks for adverse effects. Furthermore, these modest additional benefits are achieved at a relatively small additional cost, which reflects the low cost of laser treatment relative to the cost of injections with a VEGF inhibitor.
Choosing between monotherapy with a VEGF inhibitor and combination therapy with laser treatment plus a VEGF inhibitor may ultimately depend on patient preference. Laser treatment has potential complications and adds small incremental benefit to VEGF inhibitor therapy; thus, persons with different relative values for complications, blindness, and alternative outcome measures for improvement of visual acuity may prefer monotherapy with a VEGF inhibitor. For example, patients may be better suited to injections alone if more frequent injections or less vision improvement or both are preferred to the risk for laser complications. Incorporating patient preferences via shared decision making is an area in which primary care clinicians can play an especially valuable role. An understanding of treatment risks, benefits, and tradeoffs can help primary care providers respond to patients' questions.
Choice of the specific VEGF inhibitor remains controversial. If less-expensive, off-label bevacizumab is available and is as efficacious as ranibizumab, it is preferred because it is substantially cheaper. We believe that it is a reasonable and highly cost-effective option. The cost-effectiveness of VEGF Trap-Eye, by comparison, varies with dose, cost, and relative frequency of treatment (45) . Meta-analysis or other guidance about VEGF inhibitors would be valuable.
Our analysis ultimately indicates that VEGF inhibitors with or without laser treatment provide important health benefits with favorable cost-effectiveness, costing less per QALY gained than many accepted therapies. Appropriate treatment reduces societal costs and substantially improves quality of life compared with undiagnosed or untreated DME. This finding highlights the need for referral and coordination between primary care providers and ophthalmologists, enabling diagnosis and early management of this visually disabling condition.
